Morgan Stanley upgrades Fleury stock rating to Equalweight on M&A potential

Published 23/09/2025, 08:36
Morgan Stanley upgrades Fleury stock rating to Equalweight on M&A potential

Investing.com - Morgan Stanley upgraded Fleury SA (FLRY3:BZ) from Underweight to Equalweight on Tuesday, raising its price target to R$18.25 from R$12.50.

The upgrade comes as Fleury’s share price has "decoupled from fundamentals" following unconfirmed press reports involving Rede D’Or, with investor focus shifting toward potential M&A outcomes rather than standalone performance metrics.

Morgan Stanley’s previous Underweight thesis was based on limited organic growth prospects, constrained by pricing pressures and volume saturation in the diagnostics segment, despite management’s "best-in-class execution" and successful integration of Pardini.

The firm continues to observe structural challenges in the diagnostics market, including limited growth in the high-tier beneficiary base, payor efforts to reduce overutilization, industry overcapacity, and hospitals increasingly internalizing diagnostics operations.

While acknowledging Fleury’s operational excellence has helped mitigate some market pressures, Morgan Stanley believes the company’s long-term growth outlook "remains challenged" with limited upside from internal levers following the full absorption of Pardini’s synergies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.